



# YOUR RELIABLE PARTNER FROM INDIA

Smilax, the inspiration for our name, is a genus of 300-350 berries and plants that provide sustenance, shelter, and are of great medicinal value to the entire world.

At Smilax Laboratories Limited, we aspire to be the reliable source for API needs of pharmaceutical companies worldwide. Organically tuned to evolve, adapt and flourish, brand Smilax is making its presence felt in US, Europe, Japan within just five years of its inception.

#### **VISION**

Smilax shall be leading research & manufacturing partner in Active Pharmaceutical Ingredients & Advanced Drug intermediates pursuing chemistry for sustainable growth.

## **STRATEGY**

Our goal is to be a preferred provider of Active Pharmaceutical Ingredients and Advanced Drug intermediates for the Global Pharmaceutical Companies.

We use our core competence in developing cost effective chemistry solutions with regulatory compliance.

We leverage on the group's financial strength, global presence in infrastructure and environment engineering capabilities.

We invest in scale, capacity, quality and chemistry solutions to enable efficient outsourcing for our Global Pharmaceutical Customers.

- Smilax is promoted by USD 1.5 billion Hyderabad based Ramky Group, a leader in Infrastructure and Environment Engineering.
- All key functions are headed by best-in-class pharma professionals.
- Received 'Outstanding Exports Award' in Bulk Drugs Category for 3 Consecutive years from Government of India.
- Smilax manufactures APIs, Advanced Drug Intermediates and Pellets for global pharma companies
- Built up Area of 350,000 sft
- 475 Kl multiple block facility
- Plan to scale up to 1200 kl

#### MISSION

We shall ensure quality, reliability and continuous innovation thereby enhancing the sustainability & value for all stakeholders.

### WHY SMILAX

### **REGULATORY APPROVALS**



- Facilities audited and approved by USFDA and European regulatory agency.
- Smilax is an approved source for many prestigious clients, including the top five in EU, Japan, Korea and India.
- Received approval for Omeprazole CEP from EDQM
- Both sites are approved by WHO

### RESEARCH & DEVELOPMENT



- State of the art R&D centre manned by a 40 member team
- Equipped with a Kilo Lab facility, Advanced analytical infrastructure





- Facilities to meet cGMP requirements
- EHS 100% with an advantage of group expertise.

## **PRODUCT PORTFOLIO**

### **APIS OFFERED**

### **Anti-Ulceratives**

- Esomeprazole Mg Trihydrate
- Esomeprazole Sodium
- Omeprazole
- Omeprazole CEP
- Omeprazole Magnesium
- Omeprazole Sodium
- Pantoprazole Sodium Sesquihydrate
- Anti-Diabetic
- Repaglinide
- Pioglitazone

- Anti-Hypertensive / Anti-Anginal Anti-Depressant / Anti-Psychotic
- Amlodipine Besylate
- Azilsartan
- Candesartan Cilexetil
- Irbesartan
- Losartan Potassium
- Valsartan
- Olmesartan Medoxomil
- Telmisartan
- Erectile Dysfunction
- Sildenafil Citrate

- .
- AtomoxetineBlonanserin
- Citalopram HBr
- Escitalopram Oxalate
- Memantine Hcl
- Olanzapine
- Risperidone
- Anti-Migraine
- Sumatriptan Succinate

### **APIs Under Development**

- Anti-Hypertensive / Anti-Anginal
- Azilsartan Medoxomil
- Ranolazine

#### Anti-Depressant / Anti-Psychotic

• Memantine Hcl

#### Anti-Histamine

- Levocetrizine Di Hcl
- Anti-Coagulant
- Dabigatran

#### **Anti-Spasmodic**

Mirabegron

### **Erectile Dysfunction**

Tadalafil

### **Pellets**

### **Anti-Ulceratives**

- Omeprazole Pellets 7.5%, 8.5%
- Lansoprazole Pellets 8.5%, 11.2%
- Esomeprazole Pellets 8.5%, 22.5%
- Pantoprazole Sodium Pellets 15%, 25%

### Anti-Fungal

- Itraconazole Pellets 22%
- Itraconazole Pellets 40%
- Itraconazole Pellets 44%

# Scale, Quality and Compliance for a Reliable Partnership



### Corp. Office :

7th Floor, Ramky Grandiose Towers, Opp: Rolling Hills, Mind Space Road, Janardhan Reddy Nagar, Gachibowli, Hyderabad - 500 032. Telangana State, India.

E-mail: info@smilaxlabs.com • Website: www.smilaxlabs.com

Disclaimer: "Smilax Laboratories Limited respects Patent laws and conventions of Pharmaceuticals as applicable in different countries. Products covered by valid patents are not offered or supplied for commercial use in those countries. It is Buyer's / Customer's responsibility to ensure that such commercial activity does not infringe any applicable patent rights".